Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Mar 26, 2024 11:22am
51 Views
Post# 35953045

RE:RE:RE:RE:The Take-Over

RE:RE:RE:RE:The Take-OverRPINVESTOR1,

Looking back when there was this conveyor belt of private placements at $.10 where mainly Jamie and Andrew loaded up on shares with some share being bought by directors it now looks like there was a "plan" to gain voting control of the company with the intention of taking it private.  As they were doing that they went through the charade of pretending to develop the companies assets which we now know was not happening.  There was minimal effort to move the dermal injector to FDA Approval.  The rest of the assets RCH-01, RCT-01 and RCS-01 were dead in the water.

I always thought it was a bit strange that Jamie and Andrew were loading up with shares at the same time the Arbitration was taking place with the possibility of loosing the judgement. 

In a previous post I mentioned the question whether they have lined up a sale of the assets or are they as stated in the N/R planning to develop the assets with the shareholders getting a share of the profits.

If they don't have capital now to develop the assets I doubt they will have the necessary capital after this Take-Over which leads me to believe they plan to sell the assets and sprinkle a few "crumbs" (8%) to the rest of us.
<< Previous
Bullboard Posts
Next >>